Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | WNT3A | P56704 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26125738 | 0.85 | WNT3A (0.50) | KMT2APIM2PIM1WNT3ACA2 | |
| SCHEMBL1124235 | 0.80 | CA12 (0.46) | HTTPIM2PIM1WNT3ACA2 | |
| SCHEMBL11826134 | 0.79 | MMP12 (0.48) | PIM2PIM1WNT3ACA2CA12 | |
| SCHEMBL1919022 | 0.79 | MKNK1 (0.55) | PIM2PIM1WNT3ACA2CA12 | |
| SCHEMBL538208 | 0.78 | ABCC4 (0.61) | KMT2AABCC4LMNAGAATSHR | |
| SCHEMBL30433544 | 0.78 | ABCC4 (0.61) | KMT2AABCC4LMNAGAATSHR | |
| SCHEMBL11541937 | 0.78 | CYP2D6 (0.60) | PIM2PIM1CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL1221263 | 0.77 | MKNK1 (0.56) | GAANAPRTPIM2PIM1P4HTM | |
| SCHEMBL7615000 | 0.77 | TPH1 (0.55) | PTGS1PIM2PIM1 | |
| SCHEMBL7615005 | 0.77 | TPH1 (0.55) | PTGS1PIM2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212291-B1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-04 | — | — | EP | disclosed |
| EP-2212291-B1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-04 | — | — | EP | disclosed |
| US-8637513-B2 | Heterocycle phenyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637513-B2 | Heterocycle phenyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637513-B2 | Heterocycle phenyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20100261724-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-14 | — | — | US | disclosed |
| US-20100261724-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-14 | — | — | US | disclosed |
| US-20100261724-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-10-14 | — | — | US | disclosed |
| EP-2212291-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009054984-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009054984-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261724-A1 | HETEROCYCLE PHENYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | CACNA1G, CACNA1H, CACNA1I | KMT2A 3110/4885ABCC4 425/4885LMNA 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.